Last reviewed · How we verify
TECHNETIUM TC 99M OXIDRONATE
At a glance
| Generic name | TECHNETIUM TC 99M OXIDRONATE |
|---|---|
| Modality | Small molecule |
| Phase | FDA-approved |
| First approval | 1982 |
Approved indications
Common side effects
- Nausea
- Vomiting
- Injection site reactions
Serious adverse events
- Hypersensitivity reactions
- Life-threatening reactions
Key clinical trials
- Screening for Cardiac Amyloidosis With Nuclear Imaging for Minority Populations
- Contribution of the VERITON-CT Camera in Prostate Bone Radiostereotaxy (NA)
- Value of Intense Phenotyping in Heart Failure With Preserved Ejection Fraction
- Diagnosis of Bone Metastases in Breast Cancer: Bone Scintigraphy, Fluoride-PET and FDG-PET
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TECHNETIUM TC 99M OXIDRONATE CI brief — competitive landscape report
- TECHNETIUM TC 99M OXIDRONATE updates RSS · CI watch RSS